NEW YORK, July 18, 2026, 12:02 p.m. (EDT) — Viking Therapeutics, Inc. (NASDAQ:VKTX) experienced a 4.6% decline in its stock price over the past week, closing at $37.08 on Friday after a 1.95% gain for the day. Despite this weekly drop, the company's cash-adjusted valuation remains 86% higher than that of Structure Therapeutics Inc. (NASDAQ:GPCR), signaling that investors continue to assign a clinical-stage premium to Viking's pipeline.
The valuation gap underscores the market's focus on Viking's two ongoing Phase 3 injectable obesity trials, while Structure is preparing to initiate late-stage oral trials in the second half of 2026. This divergence in clinical timelines has contributed to the premium, even as both companies face significant cash burn and competitive pressures in the obesity drug space.
Financial Comparison
Balance sheets present a contrasting picture. As of March 31, Viking reported $603 million in cash, cash equivalents, and short-term investments, while Structure held $1.46 billion. Viking's disclosed funding runway extends to mid-2027, whereas Structure's reaches late 2028. The market capitalizations also differ: Viking's current market value stands at $4.31 billion, compared to Structure's $3.45 billion.
After adjusting for cash on hand, Viking's enterprise value is approximately $3.71 billion, and Structure's is $1.99 billion — a gap of roughly 86%. This disparity persists despite Structure's larger cash reserves and longer runway, highlighting the premium placed on Viking's advanced clinical data.
Analyst Sentiment and Earnings Outlook
Analyst support has bolstered the premium. On July 16, William Blair analyst Andy Hsieh reiterated his Buy rating on Viking. However, costs are escalating. FactSet's consensus estimate for Viking's 2026 loss per share has widened by 18.5% over the past three months, now standing at $4.75. The projected loss for the second quarter is $1.23 per share.
In the first quarter, Viking's operating cash outflow reached $114 million, more than double the amount from a year earlier, with research expenses totaling $150 million. This increased burn rate reflects the intensifying investment in clinical development.
Clinical Data and Pipeline
Viking's oral candidate VK2735 achieved an average weight loss of 12.2% over 13 weeks, with a placebo-adjusted average of 10.9% at the highest dose. Chief Executive Brian Lian described the results as showing "compelling efficacy" and "encouraging tolerability." Meanwhile, Structure reported a placebo-adjusted weight reduction of up to 16.3% after 44 weeks, though the studies differ in design and length. Guggenheim analyst Seamus Fernandez noted that Structure's tolerability "appears highly competitive on vomiting and discontinuations."
Viking anticipates releasing maintenance results for VK2735 in the third quarter and plans to launch a Phase 3 oral trial in the fourth quarter. No webcasts or presentations are scheduled for the upcoming week, with second-quarter earnings expected on July 29, according to FactSet.
Market Context and Risks
For the week, Viking's stock lagged behind the SPDR S&P Biotech ETF (NYSEARCA:XBI), which fell 3.00%. The broader biotech sector has faced headwinds, and near-term sector flows may become a key driver for Viking's stock.
Risks remain significant. Cross-trial comparisons can be misleading, and increased cash burn, disappointing Phase 3 outcomes, production setbacks, or the need for additional funding could erode the current valuation premium. Investors will closely monitor cash levels, research expenditure, and VK2735 maintenance data in the coming months.
The valuation premium faces a critical test on July 29, when Viking reports its second-quarter earnings. Until then, biotech sector flows may dictate short-term price movements.
